This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Takeda Pharmaceutical Company Ltd
Drug Names(s): VONOSAP Pack 400, VONOSAP Pack 800, VONOSAP (Takecab + Amolin + Clarith) [JP]
Description: VONOSAP is a triple-drug blister pack combining the acid suppressant TAKECAB tablet (generic name, vonoprazan fumarate) developed by Takeda, Amolin capsule (generic name, amoxicillin) and Clarith tablet (generic name, clarithromycin).
Takeda and Otsuka
In March 2014, Otsuka and Takeda announced that the two firms have entered into a co-promotion agreement in Japan for TAK-438 (generic name: Vonoprazan Fumarate) for the treatment of acid-related diseases. The details of this agreement are as follows:
- Otsuka will pay Takeda an up-front payment of 20 billion yen and a milestone payment upon NDA approval.
- Otsuka will receive from Takeda a percentage of the sales (based on conditions specified in the contract).
- Japan will be the area of promotion.
- Further details will not be disclosed.
Partners: Otsuka Holdings Co., Ltd.
Additional information available to subscribers only: